The 7-valent pneumococcal conjugate vaccine elicits cross-functional opsonophagocytic killing responses to Streptococcus pneumoniae serotype 6D in children

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Lee, Hyunju ^a   Cha, Jung H ^a   Nahm, Moon H ^b   Burton, Robert L ^b   Kim, Kyung Hyo ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Heptavalent pneumococcal conjugate vaccine; Pneumococcal polysaccharide type 6; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE;

ANTIBODY RESPONSE; ARTICLE; BACTERIAL STRAIN; CHILD; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; INFANT; INFECTION CONTROL; MAJOR CLINICAL STUDY; PHAGOCYTOSIS; PRESCHOOL CHILD; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

CROSS PROTECTION; FEMALE; HUMANS; INFANT; MALE; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 84885121919     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-474     Document Type: Article

References (35)

1. Center for Disease Control and Prevention Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005, 54:893-897. Center for Disease Control and Prevention.
2. Hsu KK, Shea KM, Stevenson AE, Pelton SI. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr Infect Dis J 2010, 29:289-293.
3. Bratcher PE, Park IH, Oliver MB, Hortal M, Camilli R, Hollingshead SK, Camou T, Nahm MH. Evolution of the capsular gene locus of Streptococcus pneumoniae serogroup 6. Microbiology 2011, 157:189-198. 10.1099/mic.0.043901-0, 3068628, 20929956.
4. Park IH, Moore MR, Treanor JJ, Pelton SI, Pilishvili T, Beall B, Shelly MA, Mahon BE, Nahm MH, . Active Bacterial Core Surveillance Team Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 2008, 198:1818-1822. 10.1086/593339, 18983249, Active Bacterial Core Surveillance Team.
5. Bratcher PE, Park IH, Hollingshead SK, Nahm MH. Production of a unique pneumococcal capsule serotype belonging to serogroup 6. Microbiology 2009, 155:576-583. 10.1099/mic.0.024521-0, 3706093, 19202106.
6. Bratcher PE, Kim KH, King JH, Hong JY, Moon MH. Identification of natural pneumococcal isolates expressing serotype 6D by genetic, biochemical and serological characterization. Microbiology 2010, 156:555-560. 10.1099/mic.0.034116-0, 2890086, 19942663.
7. Chang B, Otsuka T, Iwaya A, Okazaki M, Matsunaga S, Wada A. Isolation of Streptococcus pneumoniae serotypes 6C and 6D from the nasopharyngeal mucosa of healthy Japanese children. Jpn J Infect Dis 2010, 63:381-383.
8. Ho P-L, Ang I, Chow K-H, Lai EL, Chiu SS. The prevalence and characteristics of Streptococcus pneumoniae isolates expressing serotypes 6C and 6D in Hong Kong prior to the introduction of the 7-valent pneumococcal conjugate vaccine. Diagn Microbiol Infect Dis 2010, 68:439-444. 10.1016/j.diagmicrobio.2010.07.020, 20926218.
9. Kuch A, Sadowy E, Skoczyńska A, Hryniewicz W. First report of Streptococcus pneumoniae serotype 6D isolates from invasive infections. Vaccine 2010, 28:6406-6407. 10.1016/j.vaccine.2010.07.051, 20674875.
10. Mercado E, Srinivansan V, Hawkins P, Chochua S, Ochoa T, Beall B, McGee L. First report of Streptococcus pneumoniae serotype 6D in South America. J Clin Microbiol 2011, 49:2080-2081. 10.1128/JCM.00153-11, 3122696, 21430101.
11. Nahm MH, Oliver MB, Siira L, Kaijalainen T, Lambertsen LM, Virolainen A. A report of Streptococcus pneumoniae serotype 6D in Europe. J Med Microbiol 2011, 60:46-48. 10.1099/jmm.0.023853-0, 3052471, 20829399.
12. Oftadeh S, Satzke C, Gilbert GL. Identification of newly described Streptococcus pneumoniae serotype 6D by use of the Quellung reaction and PCR. J Clin Microbiol 2010, 48:3378-3379. 10.1128/JCM.00675-10, 2937698, 20610680.
13. Yao KH, Liu ZJ, Yu JG, Yu SJ, Yuan L, Nahm MH, Yang YH. Type distribution of serogroup 6 Streptococcus pneumoniae and molecular epidemiology of newly identified serotypes 6C and 6D in China. Diagn Microbiol Infect Dis 2011, 70:291-298. 10.1016/j.diagmicrobio.2011.03.015, 21546198.
14. Adam HJ, Karlowsky JA, Nichol KA, Gilmour MW, Hoban DH, Embree J, Zhanel GG. Baseline epidemiology of Streptococcus pneumoniae serotypes in Canada prior to the introduction of the 13-valent pneumococcal vaccine. Microb Drug Resist 2012, 18:176-182. 10.1089/mdr.2011.0197, 22204595.
15. Massire C, Gertz RE, Svoboda P, Levert K, Reed MS, Pohl J, Kreft R, Li F, White N, Ranken R, Blyn LB, Ecker DJ, Sampath R, Beall B. Concurrent serotyping and genotyping of pneumococci by use of PCR and electrospray ionization mass spectrometry. Clin Microbiol 2012, 50:2018-2025.
16. Baek JY, Ko KS, Song JH. Streptococcus pneumoniae serotype 6D cross-reacting with serotype 6A, 6B, and 6C factor sera. J Clin Microbiol 2011, 49:765-766. 10.1128/JCM.01933-10, 3043492, 21123526.
17. Choi EH, Lee HJ, Cho EY, Oh CE, Eun BW, Lee J, Kim MJ. Prevalence and genetic structures of Streptococcus pneumoniae serotype 6D, South Korea. Emerg Infect Dis 2010, 16:1751-1753. 10.3201/eid1611.100941, 3294534, 21029535.
18. Park SE, Lee H, Lim SY, Kim KH. Immunogenicity of 7-valent pneumococcal conjugate vaccine related to booster immunization in Korean children. Korean J Pediatr 2008, 51:622-628.
19. Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 2006, 13:1004-1009. 10.1128/CVI.00112-06, 1563573, 16960111.
20. Wang D, Burton RL, Nahm MH, Soong SJ. A four-parameter logistic model for estimating titers of functional multiplexed pneumococcal opsonophagocytic killing assay. J Biopharm Stat 2008, 18:307-325. 10.1080/10543400701697182, 18327723.
21. Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 2006, 13:165-169. 10.1128/CVI.13.2.165-169.2006, 1391943, 16467321.
22. Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, Keyserling HL, Carlone GM. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997, 4:415-422. 170543, 9220157.
23. Kim KH, Yu J, Nahm MH. Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies. Clin Diagn Lab Immunol 2003, 10:616-621. 164251, 12853394.
24. Burton RL, Nahm MH. Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20. Clin Vaccine Immunol 2012, 19:835-841. 10.1128/CVI.00086-12, 3370448, 22518015.
25. Ko KS, Baek JY, Song JH. Multidrug-Resistant Streptococcus pneumoniae Serotype 6D Clones inSouth Korea. J Clin Microbiol 2012, 50:818-822. 10.1128/JCM.05895-11, 3295089, 22170935.
26. Carvalho Mda G, Pimenta FC, Gertz RE, Joshi HH, Trujillo AA, Keys LE, Findley J, Moura IS, Park IH, Hollingshead SK, Pilishvili T, Whitney CG, Nahm MH, Beall BW, . Active Bacterial Core Surveillance Team PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. J Clin Microbiol 2009, 47:554-559. 10.1128/JCM.01919-08, 2650953, 19116353, Active Bacterial Core Surveillance Team.
27. Lee H, Nahm MH, Burton R, Kim KH. Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol 2009, 16:376-381. 10.1128/CVI.00344-08, 2650865, 19144787.
28. Lee HJ, Park SE, Kim KH. Immune response to 19A serotype after immunization of 19F containing pneumococcal conjugate vaccine in Korean children aged 12-23 months. Korean J Pediatr 2011, 54:163-168. 10.3345/kjp.2011.54.4.163, 3127150, 21738550.
29. Yu X, Gray B, Chang S, Ward JI, Edwards KM, Nahm MH. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants. J Infect Dis 1999, 180:1569-1576. 10.1086/315096, 10515817.
30. Lozano F, Rada C, Jarvis JM, Milstein C. Affinity maturation leads to differential expression of multiple copies of a kappa light-chain transgene. Nature 1993, 363:271-273. 10.1038/363271a0, 8487865.
31. Hackett J, Rogerson BJ, O'Brien RL, Storb U. Analysis of somatic mutations in kappa transgenes. J Exp Med 1990, 172:131-137. 10.1084/jem.172.1.131, 2188163, 2358776.
32. Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006, 13:356-360. 10.1128/CVI.13.3.356-360.2006, 1391962, 16522777.
33. Kim NH, Lee J, Lee SJ, Lee H, Kim KH, Park SE, Lee HJ. Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM(197) protein conjugate; Prevenar) in Korean infants: differences that are found in Asian children. Vaccine 2007, 25:7858-7865. 10.1016/j.vaccine.2007.08.022, 17931753.
34. Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, Jansen KU, Love J, Gruber WC, Emini EA, Scott DA, . 004 Study Group Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010, 126:e493-e505. 10.1542/peds.2009-3027, 20732948, 004 Study Group.
35. Silfverdal SA, Hogh B, Bergsaker MR, Skerlikova H, Lommel P, Borys D, Schuerman L. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine. Pediatr Infect Dis J 2009, 28:e276-e282. 10.1097/INF.0b013e3181b48ca3, 20118683.